In non-small cell lung cancer (NSCLC), ctDNA-based mutation detection has achieved guideline inclusion as a standard diagnostic modality for identifying actionable alterations in EGFR, KRAS, and MET, facilitating timely therapeutic intervention while circumventing the morbidity and temporal constraints associated with invasive tissue sampling procedures [5]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.